What Should Cost Per Case Be in an Independent OBL or ASC?

Most physician-owned OBLs and ASCs track cost per case as a single number. That number sits on the P&L. It moves when case volume changes. It moves when a supply invoice comes in higher than expected. But it does not show whether the number is right for a facility at your volume, your specialty mix, and your purchasing structure. Cost per case without a benchmark is not a metric. It is a guess.

Why Published Benchmarks Do Not Answer the Question

Industry figures place total supply and drug costs for independent ASCs at between 13% and 18% of net revenue. That range is real. However, it combines data from hundreds of facility types. It pulls from different ownership structures, geographic markets, and purchasing relationships. As a result, a benchmark built from multispecialty ASCs tells a cardiovascular OBL very little about its own cost position.

For cardiovascular and vascular OBLs, device and implant costs push the total higher. However, the commodity supply layer underneath those cases is where the most recoverable variance exists. That layer includes drugs, contrast agents, saline, procedure packs, and general consumables. Published benchmarks do not surface that layer at a level of detail useful to a single facility.

In practice, the comparison that produces useful information is narrower. What do independent physician-owned facilities at your volume and specialty mix pay for the same inputs you already buy? That is the question worth answering.

The Two Components That Behave Differently

Cost per case in an independent OBL or ASC has two components. They do not move for the same reasons. And they do not respond to the same interventions.

The first is procedure-driven cost. This includes implants, devices, and specialty supplies tied to the clinical work performed. These costs are visible and traceable. When they increase, there is usually an identifiable cause. Most physician-owners understand this component well.

The second is commodity supply cost. This covers drugs, contrast, saline, packs, drapes, and consumables. Every case requires these inputs. Facilities purchase them from a distributor on a contract that typically auto-renews. No single line item is large enough to trigger a review. As a result, this category drifts upward over time. Nothing inside standard reporting catches it.

Moreover, this is the component most independent facilities have never benchmarked against what similar facilities actually pay. Not because the comparison is impossible. Because the data that makes it possible has not historically been on the independent operator’s side of the table. As explored in Why Is My Per-Case Margin Declining Even Though My Schedule Is Full?, commodity cost drift compounds with volume. It becomes material well before it shows up as a clear line item problem.

What GPO Membership Actually Covers

Most independent ASCs and OBLs with a GPO assume that membership manages the commodity cost problem. In practice, it addresses part of it.

A GPO sets a contract pricing floor. However, it does not monitor whether a facility purchases at the best available rate within its tier. It does not compare your invoice pricing against what similar independent facilities pay for the same SKUs. And it does not flag when pricing drifts above market at renewal.

Furthermore, volume tier misclassification is a specific version of this problem. A facility operating at a volume that qualifies for a lower pricing tier, but was never reclassified, continues paying a higher rate. The GPO does not correct this automatically. Nobody inside the facility is positioned to catch it without an external comparison.

What Cost Per Case Actually Tells You

Cost per case is most useful when separated into its two components. Each one then needs measuring against what the market bears.

The procedure-driven component tells you whether your device and implant costs reflect your clinical volume and negotiating position. The commodity component tells you whether your supply contracts reflect the pricing available to independent facilities at your volume and specialty mix.

In most independent OBLs and ASCs, the procedure-driven side receives attention. The commodity side does not. That is where the gap lives. And for most facilities that have never run a formal benchmark comparison on that layer, the gap is structural. It has been accumulating.

The only way to know what that gap looks like at your facility is to see your actual purchase data compared against documented rates for similar independent facilities. If you want to see your number, request your complimentary supply cost analysis at vantumpartners.com. No obligation. No strings. You see the findings and keep them regardless.

Frequently Asked Questions

What is a typical cost per case for an independent ASC?

Published benchmarks place total supply and drug costs for independent ASCs between 13% and 18% of net revenue. However, specialty mix and implant volume shift that range. For cardiovascular and vascular OBLs, device costs push the total higher. These figures help with category-level orientation. They do not replace a facility-specific comparison against independent facilities at similar volume and specialty mix.

How does cost per case differ between a cardiovascular OBL and a general surgery ASC?

Cardiovascular and vascular OBLs carry higher device and implant costs per case. This reflects the cost of endovascular and interventional tools. However, the commodity supply layer is more similar across facility types. The benchmark methodology applies to both. That said, the procedure-driven cost component requires specialty-specific context to interpret correctly.

What commodity supplies have the most impact on cost per case in a physician-owned OBL?

In a cardiovascular or vascular OBL, contrast agents, saline, procedure packs, access supplies, and general consumables carry the largest per-case commodity cost impact. Facilities purchase these on a recurring basis. They are not procedure-specific. As a result, they are the inputs most likely to carry a pricing gap relative to market rates. Facilities tend to purchase them habitually rather than negotiate them actively.

How do I know if my cost per case is competitive?

The most reliable signal is a SKU-level comparison of your actual invoice pricing against what independent facilities at your volume and specialty mix pay for the same inputs. Published industry averages do not provide this. Your GPO report does not provide this either. It requires actual pricing data from comparable independent facilities. For most physician-owned OBLs and ASCs, this comparison has never been run on the commodity supply layer specifically.

Does GPO membership reduce cost per case for an independent OBL or ASC?

A GPO sets a contract pricing floor. However, it does not actively monitor whether a facility purchases at the best available rate within its tier. In practice, a commodity supply pricing gap can persist inside a GPO relationship. This is especially true when contracts auto-renew without a formal comparison against what similar independent facilities pay for the same SKUs.